Preliminary efficacy report of a novel thrombolytic agent for acute ischaemic stroke within a 5-hour window

CNS Drugs

Volumn 21, Issue 11, 2007, Pages 937-946

  Chao, A Ching ^a   Teng, Michael Mu Huo ^b   Chung, Chih Ping ^b   Weng, Hsing Yu ^b   Chen, Yen Yu ^b   Yang, Fu Yi ^b   Wang, Lee Min ^b   Hu, Han Hwa ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Human tissue urokinase type plasminogen activator, therapeutic use; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; UROKINASE;

ACUTE DISEASE; AGED; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLASGOW OUTCOME SCALE; HUMAN; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; TAIWAN; TEACHING HOSPITAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 35048812931     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721110-00005     Document Type: Article

References (22)

1. Hu HH, Sheng WY, Chu FL, et al. Incidence of stroke in Taiwan. Stroke 1992; 23: 1237-41
2. Adams HP, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 1996; 27: 1711-8
3. Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset. Japan Alteplase Clinical Trial (J-ACT) Group. Stroke 2006; 37 (7): 1810-5
4. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36 (1): 66-73
5. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351 (21): 2170-8
6. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35: 904-11
7. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1: 36-45
8. Barber PA, Parsons MW, Desmond PM, et al. The use of PWI and DWI measures in the design of "proof-of-concept" stroke trials. J Neuroimaging 2004; 14: 123-32
9. Lee SG, Kalyan N, Wilhelm J, et al. Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes. J Biol Chem 1988; 263: 2917-24
10. Fu KP, Lee S, Hetzel N, et al. Clearance of a novel recombinant tissue plasminogen activator in rabbits. Thromb Res 1988; 50: 679-85
11. Weinheimer CJ, James HL, Kalyan NK, et al. Induction of sustained patency after clot-selective coronary thrombolysis with hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. Circulation 1991; 83: 1429-36
12. Feldmann E, Daneault N, Kwan E, et al. Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990; 40: 1541-5
13. Tanaka H, Hayashi M, Date C, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction. Stroke 1985; 16: 773-80
14. Gross CR, Kase CS, Mohr JP, et al. Stroke in South Alabama: incidence and diagnostic features: a population based study. Stroke 1984; 15: 249-55
15. Hu HH, Teng MH, Hsu LC, et al. A pilot study of a new thrombolytic agent for acute ischemic stroke in Taiwan within a five-hour window. Stroke 2006 Mar; 37 (3): 918-9
16. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1), 10 June 1996 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA482.pdf [Accessed 2007 Apr 4]
17. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 33: 1581-7
18. DeGraba TJ, Hallenbeck JM, Pettigrew KD, et al. Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. Stroke 1999; 30: 1208-12
19. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7
20. Mahoney FI, Barthel D. Functional evaluation: the Barthel index. Maryland State Med J 1965; 14: 61-5
21. Jennett B, Bond M. Assessment of outcome after severe brain injury: a practical scale. Lancet 1975; 1: 480-4
22. Albanese MA, Clarke WR, Adams HP, et al. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke: the program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke 1994; 25: 1746-51